ArticleJournal of advanced research2026
Eravacycline and omadacycline Rescue multidrug-resistant Elizabethkingia anophelis: Triple-Model evaluation across in Vitro, Galleria mellonella, and murine bacteremia systems.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human Infections Caused by Flavobacteriales: Clinical Characteristics and Antimicrobial Susceptibility Patterns.Infectious disease reports · 2026Review
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionElizabethkingia anophelis has emerged as a formidable pathogen causing severe, life-threatening human infections. Treatment remains challenging due to its intrinsic multidrug resistance. OBJECTIVES AND
methodsThis study presents the first evaluation of eravacycline and omadacycline efficacy against E. anophelis in vitro and in vivo. Susceptibility testing of 197 clinical isolates employed broth microdilution. Galleria mellonella larval infection and murine bacteremia models assessed therapeutic efficacy.
resultsMinimum inhibitory concentration (MIC) analyses demonstrated potent in vitro activity against clinical isolates, with MICs as low as 0.06 mg/L and 0.125 mg/L, respectively. In the G. mellonella model, both agents significantly delayed larval mortality (P < 0.01) and improved health indices. Murine studies showed substantial reductions in bacterial burden versus saline controls, alongside significant anti-inflammatory and organ-protective effects. Eravacycline achieved complete bacterial eradication in hepatic, splenic, and pulmonary tissues.
conclusionThese findings substantiate the robust antimicrobial efficacy of eravacycline and omadacycline against E. anophelis, offering valuable insights for optimizing clinical management. They provide compelling proof-of-concept that fluorocyclines eradicate multidrug-resistant E. anophelis in vitro and in vivo, strongly supporting clinical trial investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.